Explore how the future of obesity drugs starts in preclinical discovery, addressing global challenges and advancing treatment ...
Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...
Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
This article is based on a poster originally authored by Peter Hsueh, Lili Qin, Jane Liu and Wenlin Ren. Target proteins are central to the antibody discovery process. These reagents play a critical ...
Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing integrated solutions from I to I (R) (Idea to IND), ranging from target validation and ...
Zoliflodacin, which will be marketed under the name Nuzolvence, is the first new drug to uniquely target gonorrhea infections in decades, and the first developed as part of a public-private ...
Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Vietnam Investment Review on MSN
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback